# A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer

> **NCT06172322** · PHASE1 · UNKNOWN · sponsor: **Nanjing Chia-tai Tianqing Pharmaceutical** · enrollment: 42 (estimated)

## Conditions studied

- HR Positive/HER-2 Negative Breast Cancer

## Interventions

- **DRUG:** NTQ1062 with Fulvestrant

## Key facts

- **NCT ID:** NCT06172322
- **Lead sponsor:** Nanjing Chia-tai Tianqing Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-28
- **Primary completion:** 2025-04
- **Final completion:** 2025-07
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2024-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06172322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06172322, "A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06172322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*